Search Results - "Haddad, Fadi G."

The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades by Jabbour, Elias, Short, Nicholas J, Jain, Nitin, Haddad, Fadi G, Welch, Mary Alma, Ravandi, Farhad, Kantarjian, Hagop

“…Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is accelerating. This analysis summarizes the data derived from the clinical…”
Get full text

PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience by Nasr, Sarah, Haddad, Fadi G, Khazen, Joseph, Kattan, Joseph, Trak-Smayra, Viviane

“…Abstract Introduction Immune checkpoint inhibitors have revolutionized the treatment of patients with advanced urothelial carcinoma (UC) in the frontline and…”
Get full text

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era by Haddad, Fadi G, Sasaki, Koji, Bidikian, Aram, Issa, Ghayas C, Kadia, Tapan, Jain, Nitin, Alvarado, Yesid, Short, Nicholas J, Pemmaraju, Naveen, Loghavi, Sanam, Patel, Keyur P, Kanagal-Shamanna, Rashmi, Yilmaz, Musa, Masarova, Lucia, Jabbour, Elias, Kantarjian, Hagop

“…Patients with chronic myeloid leukemia (CML) and T315I mutation generally have a poor prognosis. Their outcome in the post-ponatinib era remains unclear. We…”
Get full text

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia by Kantarjian, Hagop, Haddad, Fadi G, Jain, Nitin, Sasaki, Koji, Short, Nicholas J, Loghavi, Sanam, Kanagal-Shamanna, Rashmi, Jorgensen, Jeffrey, Khouri, Issa, Kebriaei, Partow, Alvarado, Yesid, Kadia, Tapan, Paul, Shilpa, Garcia-Manero, Guillermo, Dabaja, Bouthaina, Yilmaz, Musa, Jacob, Jovitta, Garris, Rebecca, O'Brien, Susan, Ravandi, Farhad, Jabbour, Elias

“…Historically, adults with relapsed-refractory acute lymphoblastic leukemia (ALL) experienced poor outcomes with intensive chemotherapy. This mature analysis…”
Get full text

Treatment de-escalation in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia: the emerging role of chemotherapy-free regimens by Haddad, Fadi G., Sawyers, Jacki, Short, Nicholas J.

“…The management of Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) has witnessed major progress over the past two decades…”
Get full text

Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors by Haddad, Fadi G, Kantarjian, Hagop

“…Over the past several years, advances in research, treatment, and market dynamics have impacted treatment strategies in chronic myeloid leukemia in chronic…”
Get more information

Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia by Haddad, Fadi G, Kourie, Hampig Raphael, Saleh, Khalil

“…Chemotherapy-free regimens are reshaping the treatment landscape of Philadelphia chromosome-positive acute lymphoblastic leukaemia. The report by Xie et al…”
Get full text

Reply to “Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!” by Haddad, Fadi G., Bidikian, Aram, Issa, Ghayas C.

Get full text

Treatment discontinuation in chronic myeloid leukemia: When, how, and why? by Haddad, Fadi G., Short, Nicholas J.

Get full text

Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019 by Sasaki, Koji, Haddad, Fadi G., Short, Nicholas J., Jain, Nitin, Issa, Ghayas, Jabbour, Elias, Kantarjian, Hagop

“…Abstract Background Since the introduction of BCR::ABL1 tyrosine kinase inhibitors (TKIs) in 2000, the treatment of Philadelphia chromosome (Ph)‐positive…”
Get full text

EXABS-133-ALL Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia by Haddad, Fadi G, Kantarjian, Hagop, Jabbour, Elias

Get full text

The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment‐free remission in chronic myeloid leukemia by Haddad, Fadi G., Sasaki, Koji, Issa, Ghayas C., Jabbour, Elias, Kantarjian, Hagop

Get full text

Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia? by Haddad, Fadi G, Short, Nicholas J

“…The incorporation of BCR::ABL1 tyrosine kinase inhibitors (TKIs) to intensive chemotherapy significantly improved the outcomes of patients with Philadelphia…”
Get full text

Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors by Haddad, Fadi G., Sasaki, Koji, Issa, Ghayas C., Garcia‐Manero, Guillermo, Ravandi, Farhad, Kadia, Tapan, Cortes, Jorge, Konopleva, Marina, Pemmaraju, Naveen, Alvarado, Yesid, Yilmaz, Musa, Borthakur, Gautam, DiNardo, Courtney, Jain, Nitin, Daver, Naval, Short, Nicholas J., Jabbour, Elias, Kantarjian, Hagop

“…Tyrosine kinase inhibitors (TKIs) discontinuation in patients with Philadelphia‐chromosome‐positive chronic myeloid leukemia (Ph‐positive CML) is increasingly…”
Get full text

The efficacy of homoharringtonine in pediatric acute myeloid leukemia: findings from the Chinese Children's Leukemia Group-AML 2015 Study by Catueno, Samanta, Haddad, Fadi G, Cuglievan, Branko

Get full text

Ponatinib‐review of historical development, current status, and future research by Kantarjian, Hagop M., Chifotides, Helen T., Haddad, Fadi G., Short, Nicholas J., Loghavi, Sanam, Jabbour, Elias

“…Ponatinib is a third‐generation BCR::ABL1 tyrosine kinase inhibitor (TKI) with high potency against Philadelphia chromosome (Ph)‐positive leukemias, including…”
Get full text

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial by Jabbour, Elias, Short, Nicholas J, Jain, Nitin, Huang, Xuelin, Montalban-Bravo, Guillermo, Banerjee, Pinaki, Rezvani, Katayoun, Jiang, Xianli, Kim, Kun Hee, Kanagal-Shamanna, Rashmi, Khoury, Joseph D, Patel, Keyur, Kadia, Tapan M, Daver, Naval, Chien, Kelly, Alvarado, Yesid, Garcia-Manero, Guillermo, Issa, Ghayas C, Haddad, Fadi G, Kwari, Monica, Thankachan, Jennifer, Delumpa, Ricardo, Macaron, Walid, Garris, Rebecca, Konopleva, Marina, Ravandi, Farhad, Kantarjian, Hagop

“…Ponatinib and blinatumomab are effective therapies in patients with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia, and their…”
Get full text

Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase by Haddad, Fadi G., Sasaki, Koji, Nasr, Lewis, Short, Nicholas J., Kadia, Tapan, Dellasala, Sara, Cortes, Jorge, Nicolini, Franck E., Issa, Ghayas C., Jabbour, Elias, Kantarjian, Hagop

“…ABSTRACT Background Ponatinib is a third‐generation BCR::ABL1 tyrosine kinase inhibitor (TKI) with robust activity in Philadelphia chromosome–positive…”
Get full text

Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results by Kantarjian, Hagop, Short, Nicholas J., Jain, Nitin, Sasaki, Koji, Huang, Xuelin, Haddad, Fadi G., Khouri, Issa, DiNardo, Courtney D., Pemmaraju, Naveen, Wierda, William, Garcia‐Manero, Guillermo, Kebriaei, Partow, Garris, Rebecca, Loghavi, Sanam, Jorgensen, Jeffrey, Kwari, Monica, O'Brien, Susan, Ravandi, Farhad, Jabbour, Elias

“…The combination of ponatinib, a third‐generation BCR::ABL1 tyrosine kinase inhibitor, with hyper‐CVAD chemotherapy resulted in high rates of complete molecular…”
Get full text

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? by Kantarjian, Hagop, Branford, Susan, Breccia, Massimo, Cortes, Jorge, Haddad, Fadi G., Hochhaus, Andreas, Hughes, Timothy, Issa, Ghayas C., Jabbour, Elias, Nicolini, Franck E., Sasaki, Koji, Xavier-Mahon, Francois

Get full text